<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819947</url>
  </required_header>
  <id_info>
    <org_study_id>2520140100</org_study_id>
    <nct_id>NCT02819947</nct_id>
  </id_info>
  <brief_title>Seoul National University Hospital Systemic Sclerosis Cohort</brief_title>
  <official_title>Systemic Sclerosis Cohort in Seoul National University Hospital Single Center Prospective Cohort, of Patients With Systemic Sclerosis in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish a new prospective cohort of Korean patients with systemic sclerosis and track
      the natural history of the disease over time.

      To generate new hypotheses for further investigation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a multisystem and heterogeneous disease characterized by an
      unpredictable course and high morbidity and mortality. The complexity of SSc requires
      interdisciplinary diagnostic and therapeutic management and result in a growing burden for
      all health-care systems. For this reasons, researchers are seeking new diagnostic and
      therapeutic strategies to improve management of these patients. In order to improve clinical
      care and to develop recommendations for the diagnosis and treatment of SSc, disease
      registries are used to capture and track key patient information.

      Therefore, SSc research associations and consortiums play a pivotal role to perform ongoing
      research and data collection to understanding the disease and support research projects.
      Currently, several national SSc registries in the UK, Germany, USA, Canada, Brazil, Australia
      and international registry, EUSTAR (European League Against Rheumatism scleroderma trial and
      research), have been established. However, the natural history of Asian populations are fully
      evaluated. Therefore, investigators decided to establish SSc cohort in Korean patients.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Internal organ involvement</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with internal organ involvement (Interstitial lung disease, Pulmonary arterial hypertension, Cardiac involvement, Gastrointestinal involvement, Renal involvement)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial lung disease</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with ILD (at baseline and and during follow up) by computed tomography of chest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial lung disease-progression</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with progression of ILD from baseline by computed tomography of chest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial lung disease-Changes of FVC% from baseline</measure>
    <time_frame>2-year</time_frame>
    <description>Changes of FVC% from baseline per year =FVC% at 1 year (0-unlimited%) - FVC% at baseline (0-unlimited%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial lung disease-Changes of DLCO% from baseline</measure>
    <time_frame>2-year</time_frame>
    <description>Changes of DLCO% from baseline per year =DLCO% at 1year (0-unlimited%) - DLCO% at baseline (0-unlimited%)
Negative value means improvement from baseline
Positive value means deterioration from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary arterial hypertension by echocardiography</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with pulmonary arterial hypertension (PAH) by electrocardiography
-pulmonary arterial systolic pressure: 0-unlimited (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary arterial hypertension by right heart catheterization (optional)</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with PAH confirmed by right heart catheterization mean pulmonary arterial pressure: 0-unlimited (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal cardiac function without other heart disease by echocardiography</measure>
    <time_frame>2-year</time_frame>
    <description>Ejection fraction: 0-unlimited%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pericardial effusion wihtout other heart disease by echocardiography</measure>
    <time_frame>2-year</time_frame>
    <description>Pericardial effusion: mild, moderated, severe with hemodynamic unstability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia on electrocardiogram</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with arrhythmia on electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0</measure>
    <time_frame>2-year</time_frame>
    <description>0-3 scale (0: no GI problems to 3: most severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma-Specific Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>2-year</time_frame>
    <description>0-3 (where 0 = without difficulty and 3 = unable to do)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form(SF)-36 Health Survey</measure>
    <time_frame>2-year</time_frame>
    <description>0-100 scale (a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systemic Sclerosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is an observational prospective study.</intervention_name>
    <description>Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        SSc diagnosis according to 1980 or 2013 ACR classification criteria or 2001 criteria for
        the classification of early systemic sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SSc diagnosis according to 1980 or 2013 ACR classification criteria or 2001 criteria
             for the classification of early systemic sclerosis

        Exclusion Criteria:

          -  When patients refuse to take part in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Bong Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188. Review.</citation>
    <PMID>19420368</PMID>
  </results_reference>
  <results_reference>
    <citation>Galluccio F, Walker UA, Nihtyanova S, Moinzadeh P, Hunzelmann N, Krieg T, Steen V, Baron M, Sampaio-Barros P, Kayser C, Nash P, Denton CP, Tyndall A, MÃ¼ller-Ladner U, Matucci-Cerinic M. Registries in systemic sclerosis: a worldwide experience. Rheumatology (Oxford). 2011 Jan;50(1):60-8. doi: 10.1093/rheumatology/keq355. Review.</citation>
    <PMID>21148153</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun Bong Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>systemic sclerosis</keyword>
  <keyword>cohort</keyword>
  <keyword>Korean</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

